SpringWorks Therapeutics (SWTX) to Release Quarterly Earnings on Tuesday

SpringWorks Therapeutics (NASDAQ:SWTX) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect SpringWorks Therapeutics to post earnings of ($0.76) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

SpringWorks Therapeutics Stock Up 2.7 %

Shares of SWTX opened at $33.99 on Monday. The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of -7.67 and a beta of 0.79. SpringWorks Therapeutics has a 52-week low of $18.00 and a 52-week high of $53.92. The stock has a 50 day moving average price of $33.26 and a 200 day moving average price of $37.44.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on SWTX. JPMorgan Chase & Co. upped their target price on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Wedbush restated an “outperform” rating and issued a $77.00 price objective on shares of SpringWorks Therapeutics in a research note on Thursday. Finally, HC Wainwright reiterated a “buy” rating and set a $76.00 target price on shares of SpringWorks Therapeutics in a research report on Wednesday, August 28th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $68.50.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.